Cochrane · systematic review · CD014805
Platinum‐based chemotherapy for early triple‐negative breast cancer
Mason, SRE, Willson, ML, Egger, SJ, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
14
No studies
1
Included studies
NR
No studies 1 · 6.7%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 20%High 11 · 73.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Platinum‐containing chemotherapy compared to chemotherapy without platinum in neoadjuvant therapy for early triple‐negative breast cancer
Population: neoadjuvant therapy for early triple‐negative breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
DFS at 2 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.63 [0.53, 0.75] | 8 studies · 1966 participants | High |
DFS at 5 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.63 [0.53, 0.75] | 8 studies · 1966 participants | High |
OS at 2 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.69 [0.55, 0.86] | 8 studies · 1973 participants | High |
OS at 5 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.69 [0.55, 0.86] | 8 studies · 1973 participants | High |
Pathological complete response Platinum‐containing chemotherapy vs chemotherapy without platinum | RR 1.44 [1.31, 1.59] | 15 studies · 3083 participants | High |
Platinum‐containing chemotherapy compared to chemotherapy without platinum in adjuvant therapy for early triple‐negative breast cancer
Population: adjuvant therapy for early triple‐negative breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
DFS at 2 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.69 [0.54, 0.88] | 4 studies · 1256 participants | High |
DFS at 5 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.69 [0.54, 0.88] | 4 studies · 1256 participants | High |
OS at 2 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.7 [0.5, 0.96] | 4 studies · 1256 participants | High |
OS at 5 years Platinum‐containing chemotherapy vs chemotherapy without platinum | HR 0.7 [0.5, 0.96] | 4 studies · 1256 participants | High |
Platinum‐containing chemotherapy compared to chemotherapy without platinum for early triple‐negative breast cancer
Population: early triple‐negative breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants requiring chemotherapy delays Platinum‐containing chemotherapy vs chemotherapy without platinum | RR 2.23 [1.7, 2.94] | 5 studies · 1053 participants | High |
Participants requiring dose reduction Platinum‐containing chemotherapy vs chemotherapy without platinum | RR 1.77 [1.56, 2.02] | 8 studies · 2055 participants | Moderate Downgraded: inconsistency |
Anaemia (grade III/IV) Platinum‐containing chemotherapy vs chemotherapy without platinum | RR 8.2 [5.66, 11.89] | 19 studies · 4757 participants | Moderate Downgraded: inconsistency |
Febrile neutropenia (grade III/IV) Platinum‐containing chemotherapy vs chemotherapy without platinum | RR 1.16 [0.89, 1.49] | 12 studies · 3771 participants | Moderate Downgraded: inconsistency |
Renal impairment (grade III/IV) Platinum‐containing chemotherapy vs chemotherapy without platinum | no estimate extracted | 4 studies · 463 participants | High |
Quality of life Platinum‐containing chemotherapy vs chemotherapy without platinum | no estimate extracted | NR | No studies |